| Identification | Back Directory | [Name]
NAB 2 | [CAS]
1504588-00-4 | [Synonyms]
NAB 2
alphaSYN-IN-NAB2
NAB2 >=98% (HPLC)
alphaSYN inhibitor NAB2
alphaSYN inhibitor-NAB2
N-[(2-Chlorophenyl)methyl]-1-(2,5-dimethylphenyl)-1H-benzimidazole-5-carboxamide
N-[(2-chlorophenyl)methyl]-1-(2,5-dimethylphenyl)-1H-1,3-benzodiazole-5-carboxamide | [Molecular Formula]
C23H20ClN3O | [MOL File]
1504588-00-4.mol | [Molecular Weight]
389.88 |
| Chemical Properties | Back Directory | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 5 mg/mL | [form ]
A crystalline solid | [pka]
13.04±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
alphaSYN-IN-NAB2 is an inhibitor of α-synuclein mutations. It acts by reversing the α-synuclein-induced pathological phenotype in Parkinson's disease cortical neurons and promoting E3 ubiquitin ligase Rsp5/Nedd4-dependent endosomal transport.. | [Uses]
NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease[1][2][3]. | [Definition]
ChEBI:N-(2-chlorobenzyl)-1-(2,5-dimethylphenyl)benzimidazole-5-carboxamide is an aromatic amide obtained by the formal condensation of the carboxy group of 1-(2,5-dimethylphenyl)benzimidazole-5-carboxylic acid with the amino group of 2-chlorobenzylamine. It is a member of benzimidazoles, an aromatic amide, a monocarboxylic acid amide and a member of monochlorobenzenes. | [IC 50]
α-synuclein | [storage]
Store at -20°C | [References]
[1] Tardiff DF, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science. 2013;342(6161):979-983. DOI:10.1126/science.1245321
[2] Hatstat AK, et al. Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity. RSC Chem Biol. 2021 Nov 9;3(1):96-111. DOI:10.1039/d1cb00103e |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
ZSGB-BIO
|
| Tel: |
02-400-810-9781 400810978 |
| Website: |
www.zsbio.com |
|